Cadence Raises $100 Million to Automate Chronic Care
- •Digital health startup Cadence raised $100 million in a new funding round led by Spark Capital.
- •The round values Cadence at $1.23 billion as the firm transitions toward AI-driven clinical automation.
- •Cadence is currently negotiating with the FDA to integrate AI agents into its chronic disease management programs.
Cadence, a digital health company specializing in chronic disease management, secured $100 million in a new funding round led by Spark Capital. This investment brings the company’s total valuation to $1.23 billion. The firm currently oversees care for more than 100,000 patients, using remote monitoring devices and hundreds of clinicians to treat individuals suffering from hypertension, diabetes, and heart failure.
The company plans to utilize this capital to shift its operational model by automating significant portions of clinical work using AI agents. These efforts are currently in discussion with the FDA regarding regulatory compliance. Cadence works with over 20 health system customers, though its primary billing model—charging insurers monthly for remote patient monitoring—has recently faced scrutiny from the federal health department’s watchdog and major insurers like UnitedHealthcare due to concerns over potential reimbursement abuse and care quality. CEO and founder Chris Altchek aims to scale the platform's capacity through these automated systems.